… in matured and differentiated blood cells expressing cell-surface … The activity of the proteasome
inhibitors bortezomib and … executed on cervical and breast cancer cell lines128 and in …

… determine whether proteasome inhibition in primary microglia induces ER stress, we next
examined the activation status of the three UPR branches following exposure to bortezomib or …

… to overcome proteasome inhibition with bortezomib and … to specifically kill cancer cells
using proteasome inhibition, we first … We performed differential mRNA level analysis between …

… proteasome inhibitor bortezomib (BTZ) has emerged as an effective drug for the treatment of
… pathways underlying the acquisition of bortezomib resistance in multiple myeloma. We used …

… proteasome inhibitor bortezomib. Similarly, the combination of trametinib and bortezomib,
rather than single-drug treatment, significantly suppressed the growth of MEKi-resistant cells …

… induced by proteasome inhibitors, with particular emphasis on BTZ and its implications in the
… It was demonstrated that NFKB1 was the only gene associated with a differential profile to …

… -κB inhibitor, pentoxifylline (PTX), or the proteasome inhibitor, bortezomib (BTZ), can re-sensitize
breast cancer cells to … The differential basal NF-κB activity in MCF-7 and MDA-MB-231 …

… bortezomib-… 26S proteasome is a large multicatalytic molecular machinery for protein
degradation. It is composed of at least 33 distinct proteasomal subunits [1] that can be differentiated …

… , particularly the β2-site, sensitized triple-negative breast cancer cell lines to bortezomib …
humans, several smaller studies have suggested efficacy of the proteasome inhibitor bortezomib …

… cells differentiated into macrophages (by 24 hours), the cells … The apoptotic effects of
the proteasome inhibitor bortezomib were … cells and A549 lung cancer cells. The anti-apoptotic …